title: FV Leiden mutation and risk of recurrent venous thromboembolism in Serbian population.
abstract: The absolute rate of recurrence of venous thromboembolism (VTE) is approximately 5% per year. There is a lower rate of recurrence in provoked VTE, and higher in idiopathic one. So far, there is no consensus whether hereditary thrombophilia should be considered as a persistent risk factor, and whether it requires long-term anticoagulant therapy. The aim of our study was to estimate the risk of recurrent VTE in patients carrying FV Leiden mutation in Serbian population. In retrospective study (1994-2006), we have evaluated the risk of recurrent VTE in 56 patients who are carriers of FV Leiden mutation, in comparison to group consisting of 56 patients non-carriers of FV Leiden mutation. Patients with FII G20210A and MTHFR C677T mutations, antiphospholipid antibodies, antithrombin III, protein C or protein S deficiency, malignancies and diabetes were excluded from the study. Recurrent VTE occurred in 44.6% of the patients, carriers of the FV Leiden mutations, vs. 26.7% in non-carriers group (P<0.05). The incidence rate was 3.7 and 2.2% per year, respectively. The estimated relative risk of recurrence for FV Leiden carriers was 1.67 (95% CI 0.99-2.81, P=0.049). The 60% of patients with mutation and only 13% without mutation develop rethrombosis during first year after discontinuance of therapy (P<0.01). In our study patients with symptomatic VTE who are carriers of the FV Leiden gene mutations have a higher risk of recurrent VTE than non-carriers. Our data suggest the importance of the FV Leiden mutation detection and the estimation of the clinical condition for successful secondary prophylaxis of VTE.
authors.affiliation: Blood Transfusion Institute of Serbia, Svetog Save 39, Belgrade, Serbia.
authors.forename: Mirjana
authors.initials: M
authors.lastname: Kovac
authors.forename: Danijela
authors.initials: D
authors.lastname: Mikovic
authors.forename: Nebojsa
authors.initials: N
authors.lastname: Antonijevic
authors.forename: Ljiljana
authors.initials: L
authors.lastname: Rakicevic
authors.forename: Valentina
authors.initials: V
authors.lastname: Djordjevic
authors.forename: Dragica
authors.initials: D
authors.lastname: Radojkovic
authors.forename: Ivo
authors.initials: I
authors.lastname: Elezovic
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005165:Factor V / Q000235:genetics*; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D019851:Thrombophilia / Q000150:complications / Q000188:drug therapy / Q000208:ethnology* / Q000235:genetics*; D013997:Time Factors; D054556:Venous Thromboembolism / Q000188:drug therapy / Q000208:ethnology* / Q000235:genetics*; D015022:Yugoslavia / Q000453:epidemiology
chemical_list: D000925:Anticoagulants; C095381:factor V Leiden; D005165:Factor V